Novel second generation analogs of eribulin. Part II: Orally available and active against resistant tumors in vivo

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 6, 2011, Pages 1634-1638

  Narayan, Sridhar ^a   Carlson, Eric M ^a   Cheng, Hongsheng ^a   Condon, Krista ^a   Du, Hong ^a   Eckley, Sean ^a   Hu, Yongbo ^a   Jiang, Yimin ^a   Kumar, Vipul ^a   Lewis, Bryan M ^a   Saxton, Philip ^a   Schuck, Edgar ^a   Seletsky, Boris M ^a   Tendyke, Karen ^a   Zhang, Huiming ^a   Zheng, Wanjun ^a   Littlefield, Bruce A ^a,b   Towle, Murray J ^a   Yu, Melvin J ^a  

^a EISAI INC   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Antitumor agents; Microtubule; Multi drug resistance; Oral bioavailability; P Glycoprotein; Xenograft models

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; ERIBULIN; ERIBULIN DERIVATIVE; HALAVEN; PACLITAXEL; UNCLASSIFIED DRUG; VINBLASTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CELL CULTURE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DESIGN; DRUG HALF LIFE; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; REACTION ANALYSIS; SINGLE DRUG DOSE; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; TUMOR XENOGRAFT;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; DRUG RESISTANCE, NEOPLASM; FURANS; HUMANS; KETONES; MICE; MICE, INBRED BALB C; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79952362080     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2011.01.097     Document Type: Article

References (20)

1. W. Dean-Colomb, and F.J. Esteva Semin. Oncol. 35 2008 S31
2. S. Newman Curr. Opin. Invest. Drugs 8 2007 1057
3. C. Twelves, J. Cortes, L.T. Vahdat, J. Wanders, C. Akerele, and P.A. Kaufman Clin. Breast Cancer 10 2010 160
4. J.A. Smith, L. Wilson, O. Azarenko, X. Zhu, B.M. Lewis, B.A. Littlefield, and M.A. Jordan Biochemistry 49 2010 1331
5. M.A. Jordan, K. Kamath, T. Manna, T. Okouneva, H.P. Miller, C. Davis, B.A. Littlefield, and L. Wilson Mol. Cancer Ther. 4 2005 1086
6. G. Kuznetsov, M.J. Towle, H. Cheng, T. Kawamura, K. TenDyke, D. Liu, Y. Kishi, M.J. Yu, and B.A. Littlefield Cancer Res. 64 2004 5760
7. T. Okouneva, O. Azarenko, L. Wilson, B.A. Littlefield, and M.A. Jordan Mol. Cancer Ther. 7 2008 2003
8. C. Dumontet, and M.A. Jordan Nat. Rev. Drug Discovery 9 2010 790
9. M.J. Yu, Y. Kishi, and B.A. Littlefield Anticancer Agents Nat. Prod. 2005 241
10. J.H. Lin, and M. Yamazaki Drug Metab. Rev. 35 2003 417
11. K. Goda, Z. Bacso, and G. Szabo Curr. Cancer Drug Targets 9 2009 281
12. H. Glavinas, P. Krajcsi, J. Cserepes, and B. Sarkadi Curr. Drug Delivery 1 2004 27
13. L.M. Chan, S. Lowes, and B.H. Hirst Eur. J. Pharm. Sci. 21 2004 25
14. Y. Tanigawara Ther. Drug Monit. 22 2000 137
15. M. Salerno, T. Przewloka, I. Fokt, W. Priebe, and A. Garnier-Suillerot Biochem. Pharmacol. 63 2002 1471
16. F. Frezard, E. Pereira-Maia, P. Quidu, W. Priebe, and A. Garnier-Suillerot Eur. J. Biochem. 268 2001 1561
17. W. Zheng, B.M. Seletsky, M.H. Palme, P.J. Lydon, L.A. Singer, C.E. Chase, C.A. Lemelin, Y. Shen, H. Davis, L. Tremblay, M.J. Towle, K.A. Salvato, B.F. Wels, K.K. Aalfs, Y. Kishi, B.A. Littlefield, and M.J. Yu Bioorg. Med. Chem. Lett. 14 2004 5551
18. 1H NMR and MS.
19. J. Liu, M.J. Towle, H. Cheng, P. Saxton, C. Reardon, J. Wu, E.A. Murphy, G. Kuznetsov, C.W. Johannes, M.R. Tremblay, H. Zhao, M. Pesant, F.G. Fang, M.W. Vermeulen, B.M. Gallagher Jr., and B.A. Littlefield Anticancer Res. 27 2007 1509
20. C.D. Cox, M.J. Breslin, D.B. Whitman, P.J. Coleman, R.M. Garbaccio, M.E. Fraley, M.M. Zrada, C.A. Buser, E.S. Walsh, K. Hamilton, R.B. Lobell, W. Tao, M.T. Abrams, V.J. South, H.E. Huber, N.E. Kohl, and G.D. Hartman Bioorg. Med. Chem. Lett. 17 2007 2697